Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Abacavir pharmacogenomics

Phillips, E.J. and Mallal, S. (2014) Abacavir pharmacogenomics. In: Murray, M.F., Babyatsky, M.W., Giovanni, M.A., Alkuraya, F.S. and Stewart, D.S., (eds.) Clinical Genomics: Practical Applications in Adult Patient Care. McGraw-Hill Professional.

Google Books Preview:
*Open access. Some pages may not be available


Abacavir is a nucleoside reverse transcriptase inhibitor used in combination therapy for the treatment of the human immunodeficiency virus type 1 (HIV-1) that has been associated with a hypersensitivity reaction in approximately 8% of those starting the drug.

Abacavir hypersensitivity reaction is characterized by greater than or equal to two progressive symptoms typically starting from the second week of therapy (median 9 days) with fever, malaise, nausea, vomiting, diarrhea, and later mild-to-moderate skin rash (present in 70% of patients).

Symptoms of abacavir hypersensitivity resolve rapidly with 24 to 72 hours after drug discontinuation.

A previous clinical history compatible with abacavir hypersensitivity is a contraindication to future rechallenge as severe morbidity and even mortality characterized by hypotension and shock has been described.

Item Type: Book Chapter
Murdoch Affiliation(s): Institute for Immunology and Infectious Diseases
Publisher: McGraw-Hill Professional
Copyright: © 2014 by McGraw-Hill Education
Item Control Page Item Control Page